Additionally, patients with IBD also have significantly higher concentrations of GSDMD in tissue lesions, which drive the IL‐1β and IL‐18‐mediated disruption of epithelial permeability and mucosal barriers [73]. The gene discussed is IL1B; the disease is inflammatory bowel disease.